( ; Poster session: Thursday 28th June 4...)Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop,Health

; Poster session: Thursday 28th June, 4:30 p.m. -- Combination Therapy with VELCADE, DOXIL(R) (pegylated liposomal doxorubicin) and Dexamethasone (VDD) in Newly Diagnosed Myeloma: Updated Results of a Phase II Clinical Trial * Lead investigator: Andrzej Jakubowiak, M.D., PhD., University of Michigan Comprehensive Cancer Center * Abstract #721; Poster session: Thursday 28th June, 4:30 p.m. -- Long-term Follow-Up of VELCADE, Doxorubicin and Dexamethasone (referred to as VcAD or PAD) for Untreated Multiple Myeloma * Lead investigator: Rakesh Popat, M.D., St. Bartholomew's Hospital Abstract #725; Poster session: Thursday 28th June, 4:30 p.m.

VELCADE in Previously Treated MM Patients

Data are expected to further support VELCADE as a foundation for combination therapy showing very high complete response rates in both VELCADE naive and retreated patients. Abstract highlights include:

    -- Weekly VELCADE, Cyclophosphamide and Prednisone in Myeloma

         * Lead investigator: Donna Reece, M.D., Princess Margaret Hospital

         * Abstract #639; Poster session: Thursday 28th June, 4:30 p.m.

    -- Phase II Study of VELCADE, Lenalidomide and Dexamethasone in Relapsed /

       Refractory Multiple Myeloma

         * Lead investigator: Paul Richardson, M.D., Dana-Farber Cancer

           Institute

         * Abstract #660; Poster session: Thursday 28th June, 4:30 p.m.

VELCADE Addresses Multiple Myeloma-Related Complications

New data are expected to show that VELCADE is active and safe in patients with renal impairment and bone degeneration. These data will demonstrate VELCADE differentiation in benefiting a broad range of patients. Abstract highlights include:

    -- VELCADE Plus Dexamethasone Therapy Induces Osteoblast Activation in

       Responsive Patients with Multiple Myeloma

         * Lead investigator: Shuji Ozaki,
'"/>




Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection
Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response
to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection
9. Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at
Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta
(Talotrexin) for Injection at The American Association for Cancer
Research Annual Meeting